141. Safety of the novel oral poliovirus vaccine type 2 (nOPV2) in infants and young children aged 1 to <5 years and lot-to-lot consistency of the immune response to nOPV2 in infants in The Gambia: a phase 3, double-blind, randomised controlled trial.
作者: Magnus Ochoge.;Ahmed Cherno Futa.;Ama Umesi.;Lucy Affleck.;Larry Kotei.;Baboucarr Daffeh.;Ebrima Saidy-Jah.;Anna Njie.;Oluwafemi Oyadiran.;Bassey Edem.;Musa Jallow.;Edrissa Jallow.;Simon A Donkor.;Erman Tritama.;Talha Abid.;Kathryn A V Jones.;Bernardo A Mainou.;John O Konz.;Alan Fix.;Chris Gast.;Ed Clarke.
来源: Lancet. 2024年403卷10432期1164-1175页
Novel oral poliovirus vaccine type 2 (nOPV2) has been engineered to improve the genetic stability of Sabin oral poliovirus vaccine (OPV) and reduce the emergence of circulating vaccine-derived polioviruses. This trial aimed to provide key safety and immunogenicity data required for nOPV2 licensure and WHO prequalification.
143. Global disease burden of and risk factors for acute lower respiratory infections caused by respiratory syncytial virus in preterm infants and young children in 2019: a systematic review and meta-analysis of aggregated and individual participant data.
作者: Xin Wang.;You Li.;Ting Shi.;Louis J Bont.;Helen Y Chu.;Heather J Zar.;Bhanu Wahi-Singh.;Yiming Ma.;Bingbing Cong.;Emma Sharland.;Richard D Riley.;Jikui Deng.;Josep Figueras-Aloy.;Terho Heikkinen.;Marcus H Jones.;Johannes G Liese.;Joško Markić.;Asuncion Mejias.;Marta C Nunes.;Bernhard Resch.;Ashish Satav.;Kee Thai Yeo.;Eric A F Simões.;Harish Nair.; .; .
来源: Lancet. 2024年403卷10433期1241-1253页
Infants and young children born prematurely are at high risk of severe acute lower respiratory infection (ALRI) caused by respiratory syncytial virus (RSV). In this study, we aimed to assess the global disease burden of and risk factors for RSV-associated ALRI in infants and young children born before 37 weeks of gestation.
144. Abatacept in individuals at high risk of rheumatoid arthritis (APIPPRA): a randomised, double-blind, multicentre, parallel, placebo-controlled, phase 2b clinical trial.
作者: Andrew P Cope.;Marianna Jasenecova.;Joana C Vasconcelos.;Andrew Filer.;Karim Raza.;Sumera Qureshi.;Maria Antonietta D'Agostino.;Iain B McInnes.;John D Isaacs.;Arthur G Pratt.;Benjamin A Fisher.;Christopher D Buckley.;Paul Emery.;Pauline Ho.;Maya H Buch.;Coziana Ciurtin.;Dirkjan van Schaardenburg.;Thomas Huizinga.;René Toes.;Evangelos Georgiou.;Joanna Kelly.;Caroline Murphy.;A Toby Prevost.; .
来源: Lancet. 2024年403卷10429期838-849页
Individuals with serum antibodies to citrullinated protein antigens (ACPA), rheumatoid factor, and symptoms, such as inflammatory joint pain, are at high risk of developing rheumatoid arthritis. In the arthritis prevention in the pre-clinical phase of rheumatoid arthritis with abatacept (APIPPRA) trial, we aimed to evaluate the feasibility, efficacy, and acceptability of treating high risk individuals with the T-cell co-stimulation modulator abatacept.
145. The EASL-Lancet Commission on liver health in Europe: prevention, case-finding, and early diagnosis to reduce liver-related mortality.
作者: Tom H Karlsen.;Harry Rutter.;Patrizia Carrieri.;Shira Zelber-Sagi.;Eivind Engebretsen.;Sharon Hutchinson.;Kristin Voigt.;Neil Guha.;Annalisa Berzigotti.;Georg Schomerus.;Pere Gines.;Maria Buti.;Patrizia Burra.;Michael P Manns.;Aleksander Krag.;Sabine Kleinert.
来源: Lancet. 2024年403卷10436期1522-1524页 146. Repeat placental growth factor-based testing in women with suspected preterm pre-eclampsia (PARROT-2): a multicentre, parallel-group, superiority, randomised controlled trial.
作者: Alice Hurrell.;Louise Webster.;Jenie Sparkes.;Cheryl Battersby.;Anna Brockbank.;Katherine Clark.;Kate E Duhig.;Carolyn Gill.;Marcus Green.;Rachael M Hunter.;Paul T Seed.;Zoe Vowles.;Jenny Myers.;Andrew H Shennan.;Lucy C Chappell.; .
来源: Lancet. 2024年403卷10427期619-631页
Placental growth factor (PlGF)-based testing has high diagnostic accuracy for predicting pre-eclampsia needing delivery, significantly reducing time to diagnosis and severe maternal adverse outcomes. The clinical benefit of repeat PlGF-based testing is unclear. We aimed to determine whether repeat PlGF-based testing (using a clinical management algorithm and nationally recommended thresholds) reduces adverse perinatal outcomes in pregnant individuals with suspected preterm pre-eclampsia.
147. Racial inequities in homicide rates and homicide methods among Black and White women aged 25-44 years in the USA, 1999-2020: a cross-sectional time series study.
In the USA, Black women aged 25-44 years are disproportionately murdered compared with their White counterparts. Despite ongoing efforts to reduce racial and structural inequities, the result of these efforts remains unclear, particularly in light of the COVID-19 pandemic.
148. Novel lateral flow assay for point-of-care detection of Neisseria gonorrhoeae infection in syndromic management settings: a cross-sectional performance evaluation.
作者: Remco P H Peters.;Jeffrey D Klausner.;Laura Mazzola.;Mandisa M Mdingi.;Hyunsul Jung.;Ranjana M S Gigi.;Jeremie Piton.;Joseph Daniels.;Lindsey de Vos.;Paul C Adamson.;Birgitta Gleeson.;Cecilia Ferreyra.
来源: Lancet. 2024年403卷10427期657-664页
A rapid and affordable point-of-care test is a priority for Neisseria gonorrhoeae control. WHO and Foundation for Innovative New Diagnostics (FIND) have a target product profile for a non-molecular N gonorrhoeae rapid point-of-care test that requires a clinical sensitivity of greater than 80% and a specificity over 95% to be considered useful in syndromic management; test turnaround time should be 30 min or under, and the test should cost less than US$3. A novel lateral flow assay (LFA) was developed to achieve that profile.
149. Safety and efficacy of malaria vaccine candidate R21/Matrix-M in African children: a multicentre, double-blind, randomised, phase 3 trial.
作者: Mehreen S Datoo.;Alassane Dicko.;Halidou Tinto.;Jean-Bosco Ouédraogo.;Mainga Hamaluba.;Ally Olotu.;Emma Beaumont.;Fernando Ramos Lopez.;Hamtandi Magloire Natama.;Sophie Weston.;Mwajuma Chemba.;Yves Daniel Compaore.;Djibrilla Issiaka.;Diallo Salou.;Athanase M Some.;Sharon Omenda.;Alison Lawrie.;Philip Bejon.;Harish Rao.;Daniel Chandramohan.;Rachel Roberts.;Sandesh Bharati.;Lisa Stockdale.;Sunil Gairola.;Brian M Greenwood.;Katie J Ewer.;John Bradley.;Prasad S Kulkarni.;Umesh Shaligram.;Adrian V S Hill.; .
来源: Lancet. 2024年403卷10426期533-544页
Recently, we found that a new malaria vaccine, R21/Matrix-M, had over 75% efficacy against clinical malaria with seasonal administration in a phase 2b trial in Burkina Faso. Here, we report on safety and efficacy of the vaccine in a phase 3 trial enrolling over 4800 children across four countries followed for up to 18 months at seasonal sites and 12 months at standard sites.
150. Effectiveness of a comprehensive package based on electronic medication monitors at improving treatment outcomes among tuberculosis patients in Tibet: a multicentre randomised controlled trial.
作者: Xiaolin Wei.;Joseph Paul Hicks.;Zhitong Zhang.;Victoria Haldane.;Pande Pasang.;Linhua Li.;Tingting Yin.;Bei Zhang.;Yinlong Li.;Qiuyu Pan.;Xiaoqiu Liu.;John Walley.;Jun Hu.
来源: Lancet. 2024年403卷10430期913-923页
WHO recommends that electronic medication monitors, a form of digital adherence technology, be used as a complement to directly observed treatment (DOT) for tuberculosis, as DOT is inconvenient and costly. However, existing evidence about the effectiveness of these monitors is inconclusive. Therefore, we evaluated the effectiveness of a comprehensive package based on electronic medication monitors among patients with tuberculosis in Tibet Autonomous Region (hereafter Tibet), China.
151. Efficacy of typhoid conjugate vaccine: final analysis of a 4-year, phase 3, randomised controlled trial in Malawian children.
作者: Priyanka D Patel.;Yuanyuan Liang.;James E Meiring.;Nedson Chasweka.;Pratiksha Patel.;Theresa Misiri.;Felistas Mwakiseghile.;Richard Wachepa.;Happy C Banda.;Florence Shumba.;Gift Kawalazira.;Queen Dube.;Nginache Nampota-Nkomba.;Osward M Nyirenda.;Tsion Girmay.;Shrimati Datta.;Leslie P Jamka.;J Kathleen Tracy.;Matthew B Laurens.;Robert S Heyderman.;Kathleen M Neuzil.;Melita A Gordon.; .
来源: Lancet. 2024年403卷10425期459-468页
Randomised controlled trials of typhoid conjugate vaccines among children in Africa and Asia have shown high short-term efficacy. Data on the durability of protection beyond 2 years are sparse. We present the final analysis of a randomised controlled trial in Malawi, encompassing more than 4 years of follow-up, with the aim of investigating vaccine efficacy over time and by age group.
153. Evaluating the efficacy and safety of pozelimab in patients with CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy disease: an open-label phase 2 and 3 study.
作者: Ahmet Ozen.;Voranush Chongsrisawat.;Asena Pinar Sefer.;Burcu Kolukisa.;Jessica J Jalbert.;Karoline A Meagher.;Taylor Brackin.;Hagit Baris Feldman.;Safa Baris.;Elif Karakoc-Aydiner.;Rabia Ergelen.;Ivan J Fuss.;Heather Moorman.;Narissara Suratannon.;Kanya Suphapeetiporn.;Lorah Perlee.;Olivier A Harari.;George D Yancopoulos.;Michael J Lenardo.; .
来源: Lancet. 2024年403卷10427期645-656页
CD55 deficiency with hyperactivation of complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) is an ultra-rare genetic disorder characterised by intestinal lymphatic damage, lymphangiectasia, and protein-losing enteropathy caused by overactivation of the complement system. We assessed the efficacy and safety of pozelimab, an antibody blocking complement component 5.
154. The epidemiology of Parkinson's disease.
作者: Yoav Ben-Shlomo.;Sirwan Darweesh.;Jorge Llibre-Guerra.;Connie Marras.;Marta San Luciano.;Caroline Tanner.
来源: Lancet. 2024年403卷10423期283-292页
The epidemiology of Parkinson's disease shows marked variations in time, geography, ethnicity, age, and sex. Internationally, prevalence has increased over and above demographic changes. There are several potential reasons for this increase, including the decline in other competing causes of death. Whether incidence is increasing, especially in women or in many low-income and middle-income countries where there is a shortage of high-quality data, is less certain. Parkinson's disease is more common in older people and men, and a variety of environmental factors have been suggested to explain why, including exposure to neurotoxic agents. Within countries, there appear to be ethnic differences in disease risk, although these differences might reflect differential access to health care. The cause of Parkinson's disease is multifactorial, and involves genetic and environmental factors. Both risk factors (eg, pesticides) and protective factors (eg, physical activity and tendency to smoke) have been postulated to have a role in Parkinson's disease, although elucidating causality is complicated by the long prodromal period. Following the establishment of public health strategies to prevent cardiovascular diseases and some cancers, chronic neurodegenerative diseases such as Parkinson's disease and dementia are gaining a deserved higher priority. Multipronged prevention strategies are required that tackle population-based primary prevention, high-risk targeted secondary prevention, and Parkinson's disease-modifying therapies for tertiary prevention. Future international collaborations will be required to triangulate evidence from basic, applied, and epidemiological research, thereby enhancing the understanding and prevention of Parkinson's disease at a global level.
155. Undervaccination and severe COVID-19 outcomes: meta-analysis of national cohort studies in England, Northern Ireland, Scotland, and Wales.
Undervaccination (receiving fewer than the recommended number of SARS-CoV-2 vaccine doses) could be associated with increased risk of severe COVID-19 outcomes-ie, COVID-19 hospitalisation or death-compared with full vaccination (receiving the recommended number of SARS-CoV-2 vaccine doses). We sought to determine the factors associated with undervaccination, and to investigate the risk of severe COVID-19 outcomes in people who were undervaccinated in each UK nation and across the UK.
156. Chemoprevention for malaria with monthly intermittent preventive treatment with dihydroartemisinin-piperaquine in pregnant women living with HIV on daily co-trimoxazole in Kenya and Malawi: a randomised, double-blind, placebo-controlled trial.
作者: Hellen C Barsosio.;Mwayiwawo Madanitsa.;Everlyne D Ondieki.;James Dodd.;Eric D Onyango.;Kephas Otieno.;Duolao Wang.;Jenny Hill.;Victor Mwapasa.;Kamija S Phiri.;Kenneth Maleta.;Miriam Taegtmeyer.;Simon Kariuki.;Christentze Schmiegelow.;Julie R Gutman.;Feiko O Ter Kuile.
来源: Lancet. 2024年403卷10424期365-378页
The efficacy of daily co-trimoxazole, an antifolate used for malaria chemoprevention in pregnant women living with HIV, is threatened by cross-resistance of Plasmodium falciparum to the antifolate sulfadoxine-pyrimethamine. We assessed whether addition of monthly dihydroartemisinin-piperaquine to daily co-trimoxazole is more effective at preventing malaria infection than monthly placebo plus daily co-trimoxazole in pregnant women living with HIV.
157. Indomethacin with or without prophylactic pancreatic stent placement to prevent pancreatitis after ERCP: a randomised non-inferiority trial.
作者: B Joseph Elmunzer.;Lydia D Foster.;Jose Serrano.;Gregory A Coté.;Steven A Edmundowicz.;Sachin Wani.;Raj Shah.;Ji Young Bang.;Shyam Varadarajulu.;Vikesh K Singh.;Mouen Khashab.;Richard S Kwon.;James M Scheiman.;Field F Willingham.;Steven A Keilin.;Georgios I Papachristou.;Amitabh Chak.;Adam Slivka.;Daniel Mullady.;Vladimir Kushnir.;James Buxbaum.;Rajesh Keswani.;Timothy B Gardner.;Nauzer Forbes.;Amit Rastogi.;Andrew Ross.;Joanna Law.;Patrick Yachimski.;Yen-I Chen.;Alan Barkun.;Zachary L Smith.;Bret Petersen.;Andrew Y Wang.;John R Saltzman.;Rebecca L Spitzer.;Collins Ordiah.;Cathie Spino.;Valerie Durkalski-Mauldin.; .
来源: Lancet. 2024年403卷10425期450-458页
The combination of rectally administered indomethacin and placement of a prophylactic pancreatic stent is recommended to prevent pancreatitis after endoscopic retrograde cholangiopancreatography (ERCP) in high-risk patients. Preliminary evidence suggests that the use of indomethacin might eliminate or substantially reduce the need for stent placement, a technically complex, costly, and potentially harmful intervention.
160. Standard-of-care systemic therapy with or without stereotactic body radiotherapy in patients with oligoprogressive breast cancer or non-small-cell lung cancer (Consolidative Use of Radiotherapy to Block [CURB] oligoprogression): an open-label, randomised, controlled, phase 2 study.
作者: Chiaojung Jillian Tsai.;Jonathan T Yang.;Narek Shaverdian.;Juber Patel.;Annemarie F Shepherd.;Juliana Eng.;David Guttmann.;Randy Yeh.;Daphna Y Gelblum.;Azadeh Namakydoust.;Isabel Preeshagul.;Shanu Modi.;Andrew Seidman.;Tiffany Traina.;Pamela Drullinsky.;Jessica Flynn.;Zhigang Zhang.;Andreas Rimner.;Erin F Gillespie.;Daniel R Gomez.;Nancy Y Lee.;Michael Berger.;Mark E Robson.;Jorge S Reis-Filho.;Nadeem Riaz.;Charles M Rudin.;Simon N Powell.; .
来源: Lancet. 2024年403卷10422期171-182页
Most patients with metastatic cancer eventually develop resistance to systemic therapy, with some having limited disease progression (ie, oligoprogression). We aimed to assess whether stereotactic body radiotherapy (SBRT) targeting oligoprogressive sites could improve patient outcomes.
|